Business
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.
About this update from Quest Diagnostics Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":391,"olType":false},{"type":"text","content":"SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.","length":223,"tagName":"p"},{"type":"image","alt":"questhealth.com logo (PRNewsfoto/Quest Diagnostics)","displaySize":"","headline":null,"caption":"questhealth.com logo (PRNewsfoto/Quest Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":190,"url":"https://media.zenfs.com/en/prnewswire.com/596f9c53c019a633fa68d8b76e9b4722"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xbQw7xiL7B4q082fmq5nYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzNQ--/https://media.zenfs.com/en/prnewswire.com/596f9c53c019a633fa68d8b76e9b4722","width":400,"height":190}},"href":"https://mma.prnewswire.com/media/2691025/Quest_Diagnostics_questhealth_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our more than 9% revenue growth, almost entirely organic, and approximately 13% adjusted diluted earnings per share growth reflect our team's disciplined execution of our strategy to deliver innovative diagnostic solutions for our customers' evolving needs," said Jim Davis, Chairman, CEO and President. "We are raising our revenue and EPS guidance for the year, given our robust first quarter performance and continued strategic focus."","length":466,"tagName":"p"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"text","content":"Serving Clinicians and Health Systems","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content"...